Skip to main content
Premium Trial:

Request an Annual Quote

NIH Took Note

In early January, in response to a comment posted to DrugMonkey's blog, researcher-bloggers suggested that the National Institutes of Health take a tip from the Canadian Institutes of Health Research's CV format. The Canadian format includes a designated place for grant applicants to list any expected interruptions or delays to their work. In an NIH notice posted this week, the agency announces a modification to its biographical sketch format — applicants are now able to list any potential disruptions to their research programs within their personal statements. In response to this change, DrugMonkey says "Thank you, NIH! This is a very nice step to help those, generally women, who have had the … gall to let actual life get in the way of their scientific careers." Commenters at this blog also welcome the change, though some are cautious. Dr. O says that NIH's biosketch modification is "definitely a step in the right direction," while studyzone is wary of the potential that some might misuse the information an investigator now has the option to include.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.